COLUMBIA, MD, Oct. 3, 2016 /CNW/ - Medifocus, Inc. (OTCQX:MDFZF
and TSXV:MFS.V) ("Medifocus" or the "Company"), a biotechnology
company with a portfolio of medical products encompassing
thermotherapy systems for the treatment of Benign Prostatic
Hyperplasia (BPH) and Breast Cancer, today announced the
appointment of William Jow, M.D. to
the position of Chief Executive Officer, effective October 1, 2016, replacing Augustine Y. Cheung, Ph.D., the founder of the
Company.
"We thank Dr. Cheung for his service at Medifocus and wish Dr.
Cheung the best in the next phase of his career." said Mr.
Grant Walsh, Chairman of the Board
of Directors. "Dr. Jow has served Medifocus as Medical Director
since 2014 and provided invaluable advisory services to Medifocus.
He was appointed President of the Company in March 2016 and has successfully reduced operating
expenses and improved gross margin. He has demonstrated his
leadership and vision in moving the Prolieve® business
to a more sustainable path in the last six months. His knowledge in
urology and the urology market in the U.S. will benefit Medifocus
in many ways. As a result, we saw marked improvements in operation
efficiency and financial results for the quarter ended June 30, 2016."
Dr. William Jow, the new Chief
Executive Officer of Medifocus, commented, "As a practicing
urologist who has been using Prolieve® and other
minimally invasive procedures to treat patients with BPH symptoms,
I can say with confidence that Prolieve® therapy is the
best alternative to BPH medications, surgeries and other
thermal/RF/laser vaporization procedures for a vast majority of BPH
patients. Prolieve® Thermodilatation is the only
TUMT system equipped with a dilating balloon that compresses the
prostatic urethra during treatment. Such tissue compression
allows effective thermotherapy to be delivered at a lower microwave
energy which translates into better patient comfort and safer
operation. Thermodilatation also assures a patent
post-treatment prostatic urethra that contributes to a much lower
post-treatment catheterization rate. More importantly, all
Prolieve® consoles are equipped with an automatic
shut-off safety mechanism which keeps the rectal temperature below
41 to 42 degrees Celsius as demonstrated in our thermal mapping
studies. All these unique features render
Prolieve® a safe, effective and well-tolerated
outpatient procedure as confirmed in our recent 10-year Post Market
Follow-up Study. To date, over 100,000 Prolieve®
cases have been performed in the U.S."
Dr. Jow added, "Thanks to our corporate restructuring efforts
over the past six months, Medifocus has emerged as a much stronger
company poised for future growth. Our team has expanded to
include V.P. of Operations Stuart E.
Katz, M.D., urologist, IT/Marketing Specialist Warren Sekino and other medical expert
consultants. Together, we are proud to provide this
state-of-the-art, safe and effective treatment to many more BPH
patients in the U.S. and beyond."
William W. Jow, M.D.
received his M.D. degree from New York
University in 1986. Following his surgical and
urological residencies at Mount Sinai Medical Center and University
of Buffalo, and fellowship training at Weill Cornell Medical
College, he had served as Assistant Professor at Rutgers Robert
Wood Johnson Medical School in New Jersey. Dr. Jow has been
in private practice for over 20 years, and has been Chairman of
Urology at Hackensack Meridian Health - Bayshore Hospital in
Holmdel, New Jersey, and served on
its Medical Executive Committee since 2012. He has also
served as consultants to various sales and product development
ventures before joining Medifocus as Scientific & Business
Development Consultant and Medical Director in 2014.
About Medifocus, Inc.:
Medifocus, Inc. (TSXV-MFS, OTC-MDFZF) is a biotechnology company
with a portfolio of medical technologies that utilize heat
activation to treat conditions ranging from prostate diseases to
breast cancer. Heat is known to accelerate numerous
biochemical and cellular processes, and Medifocus' portfolio relies
on this fact to improve clinical outcome. Its Prolieve®
Thermodilatation System offers relief from Benign Prostatic
Hyperplasia (BPH) to millions of men with a simple, 45-minute
in-office treatment. Its APA-1000™ Breast Cancer Thermotherapy
System is currently in phase 3 clinical trials, and is designed to
treat localized and locally advanced breast cancers through the
application of heat alone or in combination with
chemotherapy.
For more details, please visit:
www.medifocusinc.com
www.prolieve.com
www.facebook.com/pages/Medifocus-Inc-Company-Page/546315028715627
Neither TSX Venture Exchange nor its Regulation Services
Provider (as that term is defined in policies of the TSX Venture
Exchange) accepts responsibility for the adequacy or accuracy of
this release.
SOURCE Medifocus Inc.
